Stocks
Constellation Pharmaceuticals Financial Statements (CNST) |
||||||||||
| Constellation Pharmaceuticalssmart-lab.ru | % | 2016 | 2017 | 2018 | 2019 | 2020 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 31.12.2016 | 31.12.2017 | 14.03.2019 | 10.03.2020 | 24.02.2021 | 10.05.2021 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||
| Operating Income, bln rub | -33.7 | -39.1 | -61.2 | -86.1 | -124.8 | -139.1 | ||||
| EBITDA, bln rub | ? | -33.0 | -34.0 | -59.1 | -82.7 | -122.8 | -138.2 | |||
| Net profit, bln rub | ? | -34.5 | -35.4 | -59.9 | -85.6 | -126.4 | -141.0 | |||
| OCF, bln rub | ? | -32.8 | -37.6 | -48.8 | -72.2 | -111.4 | -125.1 | |||
| CAPEX, bln rub | ? | 0.948 | 0.582 | 0.476 | 0.699 | 0.946 | 1.40 | |||
| FCF, bln rub | ? | -33.7 | -38.2 | -49.3 | -72.9 | -112.4 | -126.5 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | ||||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 33.7 | 39.1 | 61.2 | 86.1 | 124.8 | 139.1 | ||||
| Cost of production, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| R&D, bln rub | 27.9 | 32.6 | 48.8 | 66.5 | 95.5 | 106.2 | ||||
| Interest expenses, bln rub | 1.35 | 0.901 | 0.228 | 2.12 | 2.86 | 2.01 | ||||
| Assets, bln rub | 38.7 | 19.1 | 118.9 | 399.1 | 441.9 | 402.7 | ||||
| Net Assets, bln rub | ? | 17.3 | 7.40 | 104.2 | 337.6 | 410.7 | 377.3 | |||
| Debt, bln rub | 10.6 | 4.10 | 0.000 | 32.2 | 4.23 | 3.37 | ||||
| Cash, bln rub | 36.9 | 16.4 | 114.6 | 383.9 | 421.4 | 382.1 | ||||
| Net debt, bln rub | -26.3 | -12.3 | -114.6 | -351.7 | -417.2 | -378.7 | ||||
| Ordinary share price, rub | 4.01 | 47.1 | 28.8 | 34.0 | ||||||
| Number of ordinary shares, mln | 48.0 | 11.7 | 12.0 | 28.2 | 28.2 | 47.8 | ||||
| Market cap, bln rub | 0 | 0 | 48 | 1 326 | 811 | 1 624 | ||||
| EV, bln rub | ? | -26 | -12 | -67 | 974 | 394 | 1 245 | |||
| Book value, bln rub | 17 | 7 | 104 | 338 | 411 | 377 | ||||
| EPS, rub | ? | -0.72 | -3.03 | -5.00 | -3.04 | -4.49 | -2.95 | |||
| FCF/share, rub | -0.70 | -3.27 | -4.11 | -2.59 | -3.99 | -2.64 | ||||
| BV/share, rub | 0.36 | 0.63 | 8.69 | 12.0 | 14.6 | 7.89 | ||||
| FCF yield, % | ? | -102.6% | -5.50% | -13.9% | -7.79% | |||||
| ROE, % | ? | -199.3% | -478.4% | -57.5% | -25.3% | -30.8% | -37.4% | |||
| ROA, % | ? | -89.2% | -185.2% | -50.4% | -21.4% | -28.6% | -35.0% | |||
| P/E | ? | 0.00 | 0.00 | -0.80 | -15.5 | -6.42 | -11.5 | |||
| P/FCF | 0.00 | 0.00 | -0.97 | -18.2 | -7.22 | -12.8 | ||||
| P/BV | ? | 0.00 | 0.00 | 0.46 | 3.93 | 1.97 | 4.30 | |||
| EV/EBITDA | ? | 0.80 | 0.36 | 1.13 | -11.8 | -3.20 | -9.01 | |||
| Debt/EBITDA | 0.80 | 0.36 | 1.94 | 4.26 | 3.40 | 2.74 | ||||
| R&D/CAPEX, % | 2 941% | 5 604% | 10 246% | 9 508% | 10 095% | 7 597% | ||||
| Constellation Pharmaceuticals shareholders | ||||||||||
